Revitty, Inc. Q3 2024 Financial Results

Revitty, Inc. (Ticker: RVTT) announced its third-quarter 2024 financial results on November 2, 2024, with CEO Prahlad Singh and CFO Max Krakowiak leading the call. The company reported a total adjusted revenue of $684 million, marking a 2% organic growth and an adjusted EPS of $1.28, which surpassed expectations by $0.16.

Adjusted operating margins improved to 28.3%, and the free cash flow for the quarter was robust at $135 million. Despite a cautious outlook for the full year, with organic growth projections now adjusted to 0% to 1%, Revitty remains optimistic about its diagnostics and software sectors and has announced a significant $1 billion share repurchase authorization.

Key Takeaways

• Revitty reported $684 million in adjusted revenues and a 2% organic growth for Q3 2024.
• The adjusted EPS of $1.28 exceeded expectations by $0.16.
• Free cash flow stood at $135 million for the quarter, contributing to a year-to-date total of $427 million.
• Adjusted operating margins improved by 80 basis points year-over-year to 28.3%.
• The company revised its full-year organic growth outlook to 0% to 1%, chiefly due to slower demand in China.
• A new $1 billion share repurchase authorization has been announced.
• Investor day is scheduled for November 21, 2024, at the new headquarters in Boston.

Company Outlook

• Q4 organic growth is anticipated between 3% to 5%.
• Full-year revenue for 2024 is expected to range between $2.75 billion and $2.77 billion.
• Adjusted EPS guidance has been raised to $4.83 to $4.87.
• The company plans to provide guidance for 2025 during the Q4 earnings call.

Bearish Highlights

• The life sciences segment experienced a 3% decline in organic growth due to underperformance in instrumentation.
• Slower demand in China is impacting revenue projections.
• The launch of new TB automation has been delayed to Q1 2025 due to regulatory queries.

Bullish Highlights

• Diagnostics revenues rose 6% to $383 million, driven by reproductive health and immunodiagnostics.
• The software segment is projected to grow in the low double digits for the year.
• The company actively repurchased shares, buying back $154 million worth in Q3.

Misses

• Full-year organic growth outlook downgraded from 2% to a range of 0% to 1%.
• Recovery in instruments was slower than expected.

Q&A Highlights

• Concerns regarding the drug discovery market and mixed signals from CROs and large pharma were discussed.
• Performance in China was worse than expected as customers await stimulus funding.
• The reagents business showed sequential improvement and mid-single-digit growth.
• Potential tariff impacts under a Trump presidency were speculated, but Revitty refrained from speculation.

Revitty's third-quarter performance showed resilience, with the company beating EPS expectations and showing growth in key sectors. Despite market challenges, particularly in China, Revitty is making strategic moves, including share repurchases and launching innovative AI-driven products. Investors should look forward to the upcoming investor day for more insights into the company's strategies and growth prospects.

InvestingPro Insights

Revitty's recent financial performance aligns with key metrics from InvestingPro. The company's adjusted EPS of $1.28, surpassing expectations, is indicative of expected net income growth this year. Solid free cash flow of $135 million for the quarter ($427 million year-to-date) shows financial health, supported by a market cap of $14.93 billion USD. The new $1 billion share repurchase authorization underscores investor confidence, suggesting stability in a challenging environment. However, trading at a high P/E ratio of 90.65 highlights investor expectations regarding future growth, especially in diagnostics and software sectors.

Full Transcript – Revitty Inc (RVTY) Q3 2024:

Operator: Hello everyone and welcome to Revitty’s third quarter 2024 earnings conference call. My name is Lydia and I will be your Operator today. After the prepared questions, there will be an opportunity to ask questions. If you’d like to ask a question during Q&A, you can do so by pressing star followed by one on your telephone keypad. I’ll now hand you over to Steve Willoughby, Head of Investor Relations to begin. Please go ahead.

Steve Willoughby: Thank you Operator. Good morning everyone and welcome to Revitty’s third quarter 2024 earnings conference call. On the call with me today are Prahlad Singh, our President and Chief Executive Officer, and Max Krakowiak, our Senior Vice President and Chief Financial Officer. I’d like to remind you of the Safe Harbor statements outlined in our press release issued earlier this morning and also those in our SEC filings. Statements or comments made on this call may be forward-looking statements which may include but may not be limited to financial projections or other statements of the company’s plans, objectives, expectations or intentions. The company’s actual results may differ significantly from those projected or suggested due to a variety of factors which are discussed in detail in our SEC filings. Any forward-looking statements made today represent our views as of today. We disclaim any obligation to update these forward-looking statements in the future, even if our estimates change, so you should not rely on any of today’s statements as representing our views as of any date after today. During this call, we will be referring to certain non-GAAP financial measures. A reconciliation of the measures we plan to use during this call to the most directly comparable GAAP measures is available as an attachment to our earnings press release. I’ll now turn it over to our President and Chief Executive Officer, Prahlad Singh. Prahlad?

Prahlad Singh: Thank you Steve, and good morning everyone. Revitty’s strong execution was again on display during the third quarter. Our total revenue, adjusted operating margin and adjusted EPS each came in better than anticipated. Our adjusted operating margins increased by 80 basis points year-over-year to 28.3% in the quarter due to positive impact from our productivity initiatives. We also generated $135 million of free cash flow, resulting in 100% cash flow conversion this year.

The company plans to remain active with its share repurchase program, returning over 100% of cash flow through buybacks and dividends. We expect our diagnostic businesses to continue strong, with signs of recovery in life sciences, reagents, and software sectors. We remain cautious about the capital equipment demand from pharma customers in Q4, anticipating organic growth to be 3% to 5%, resulting in full-year growth outlook adjustment to 0% to 1%. Our strong operational execution leads us to raise our adjusted EPS for the year to a range of $4.83 to $4.87.

Optimism remains for recovery in key markets, with a focus on innovations, including several new AI-driven products launched to improve customer experience.

Max Krakowiak: Thanks Prahlad, and good morning everyone. As Prahlad mentioned, we performed well in Q3, exceeding earnings expectations once again. We generated total adjusted revenues of $684 million in the quarter, reflecting 2% organic growth. Adjusted operating margins were strong and free cash flow conversion remains stable at 100%. We are well positioned as we head into Q4, maintaining a strong balance sheet while actively repurchasing shares with a new $1 billion authorization. Overall, we look forward to providing further insights at our investor day.

Operator: Thank you. This concludes our call. You may now disconnect your line.